short chain dehydrogenase/reductase family 16C member 6, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SDR16C6P profile across patient tissues and cancer cell-line models. SDR16C6P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SDR16C6P is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, SDR16C6P RNA expression shows 6,315 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUSC, and STAD as cancer lineages where SDR16C6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDR16C6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDR16C6P survival associations across molecular data types. SDR16C6P RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDR16C6P RNA expression–survival associations across cancer types. High SDR16C6P expression shows unfavorable associations in ACC, UVM, KICH, BLCA, UCS and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SDR16C6P RNA expression.
This table summarizes SDR16C6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SDR16C6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDR16C6P shows lower tumor expression in LUSC and LUAD. The LUSC box plot shows higher SDR16C6P RNA expression in normal versus tumor tissue (log2 FC = −0.067, t-test p = .005).
This table shows molecular features associated with SDR16C6P in patient tissues and cancer cell lines. In patient samples, SDR16C6P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SDR16C6P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS.
